$IKT Inhibikase Therapeutics, Inc. - The CEO is making an

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Emigrant Partners Expands Presence with Novare Capital Investment Emigrant Partners, a leader in the wealth and asset management industry, has recently announced an investment in Novare Capital Management, a prominent independent firm managing $1.8 billion in assets. This strategic partnership is set to empower Novare's growth while reinforcing its mission to serve...

Understanding Recent Corporate Transactions In a significant turn of events for investors, several companies are currently under investigation regarding their corporate actions and potential implications for shareholders. This article delves into the transactions involving Premier, Inc. (NASDAQ: PINC), Metsera, Inc. (NASDAQ: MTSR), and 89bio, Inc. (NASDAQ: ETNB),...

Innovative Collaboration in Addiction Treatment Branded Legacy, Inc. (OTC: BLEG) is making strides in public health by forming a revolutionary partnership with McMaster University, an esteemed institution recognized for its influential research in addiction medicine and clinical trials. This strategic alliance involves Branded Legacy's wholly-owned subsidiary, Bio-Legacy...

Insights on CTV Advertising Rankings Pixalate, a standout leader in ad fraud protection and compliance analytics, has unveiled a comprehensive look at the top 100 Connected TV (CTV) Bundle IDs that dominate global open programmatic ad spend. This research gives a snapshot into how different platforms stack up in terms of ad effectiveness across CTV applications....

OneMain Gears Up for Q2 Insights Mark your calendars, folks, because OneMain Holdings, Inc. (NYSE: OMF) is about to spill the beans on their second quarter 2026 performance on July 29. They're set to unleash their earnings report bright and early that Wednesday, right before the market opens. It's the kind of early bird special any investor keen on understanding the...